AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

Shots:

• The P-IIIb DIALIZE study results involve assessing of Lokelma vs PBO in n 196 patients on hemodialysis with hyperkalemia in ESRD
• The P-IIIb DIALIZE study resulted in maintaining normal potassium level (4-5 mmol/L) in 41.2% patients receiving Lokelma vs 1% receiving PBO, presented at ERA-EDTA
• Lokelma is an oral, formulated as suspension and commercially available in the US & EU for the treatment of hyperkalemia in adults

Click here to read full press release/ article | Ref: AstraZeneca | Image: Coroflot